FDA on Peptides: A New Landscape for Compounders

FDA on Peptides: A New Landscape for Compounders

Washington, D.C. — The Food and Drug Administration's evolving posture toward compounded peptide products is reshaping the regulatory terrain for pharmacies, outsourcing facilities, and the broader peptide therapeutics industry, according to a client alert published by law firm Latham & Watkins LLP titled "FDA on Peptides: A New Landscape for Compounders." The alert signals that compounders operating in the peptide space face a materially different — and more constrained — regulatory environment than in years past, as FDA sharpens its scrutiny of bulk drug substances, safety signals, and the boundaries between traditional compounding and unauthorized drug manufacturing.

While the underlying Latham & Watkins publication was not available in full detail at the time of this report, its title and framing point to a broader trend that has been building for several years: FDA's increasing willingness to police the compounding of popular peptides — including GLP-1 receptor agonists such as semaglutide and tirzepatide, as well as research-grade peptides like BPC-157 — through bulk drug substance determinations, import alerts, warning letters, and enforcement guidance.

Why This Matters for the Peptide Industry

Peptide compounding sits at the intersection of two powerful market forces: surging consumer demand for GLP-1 weight-loss and metabolic drugs, and a longstanding cottage industry of compounding pharmacies and telehealth platforms that have stepped in to fill supply gaps left by branded manufacturers like Novo Nordisk and Eli Lilly. During periods when FDA listed semaglutide and tirzepatide as being in shortage, compounders were permitted under federal law to produce copies under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FDCA). Once FDA formally removed those shortage designations, however, that legal safe harbor narrowed considerably.

Beyond the GLP-1 category, FDA has also taken a harder line on other peptides — including BPC-157, thymosin beta-4, and various "research chemical" peptides marketed for anti-aging, muscle recovery, or performance enhancement — citing insufficient safety data, lack of an approved use, and concerns about impurities and dosing consistency in compounded formulations.

For an industry that has grown rapidly on the back of telehealth prescribing and direct-to-consumer marketing, these developments mean that the assumptions many compounders relied on are shifting quickly and without much room for error.

Key Regulatory Levers FDA Is Using

• Bulk drug substance lists: FDA maintains lists under Sections 503A and 503B that determine which active pharmaceutical ingredients compounders may legally use. Peptides not on the approved bulks lists, or those explicitly excluded, cannot lawfully be compounded outside limited exceptions.
• Shortage status determinations: Once FDA declares a drug shortage resolved, compounded copies of that drug generally lose their regulatory justification, exposing pharmacies that continue producing them to enforcement risk.
• Warning letters and import alerts: FDA has issued warning letters to compounders and placed certain peptide raw materials on import alert lists, restricting the flow of active ingredients from overseas suppliers.
• Safety and quality concerns: Agency statements have repeatedly flagged risks associated with impurities, incorrect dosing, and lack of clinical data for many compounded peptides, particularly those never subject to FDA approval in any form.

What This Means for Compounders, Prescribers, and Patients

According to sources familiar with the regulatory landscape, the practical effect of FDA's tightening approach is a narrowing of the legal space in which compounding pharmacies and outsourcing facilities can operate. Key implications include:

• Increased compliance risk: Compounders that continue producing peptides no longer eligible for shortage-based compounding — or substances absent from the applicable bulks list — face heightened exposure to FDA warning letters, injunctions, and potential enforcement actions.
• Supply chain scrutiny: Sourcing of active pharmaceutical ingredients, particularly from overseas manufacturers, is likely to draw closer FDA and state board of pharmacy attention.
• Telehealth exposure: Platforms that have built business models around prescribing compounded peptides may need to reassess their offerings in light of shifting shortage determinations and bulk substance eligibility.
• State-level variability: State boards of pharmacy retain independent authority over compounding practices, meaning compliance obligations can differ significantly by jurisdiction even as federal policy evolves.

For patients, the tightening landscape may translate into reduced access to lower-cost compounded alternatives to branded GLP-1 drugs, alongside continued FDA messaging emphasizing the safety risks of unapproved peptide products sold outside traditional pharmacy channels.

Next Steps and What to Watch

Industry participants should watch for several developments in the coming months, including further FDA guidance documents addressing specific peptides, potential updates to the 503A and 503B bulk drug substance lists, and continued enforcement actions against compounders and suppliers deemed out of compliance. Litigation challenging FDA's shortage-resolution determinations for semaglutide and tirzepatide, brought by industry trade groups, also remains a factor that could influence how aggressively the agency pursues enforcement against compounders in the near term.

Compounding pharmacies, outsourcing facilities, and telehealth companies operating in this space are likely to seek legal counsel — as reflected in the Latham & Watkins alert — to reassess their formularies, sourcing practices, and marketing claims in light of FDA's sharpened enforcement posture.

This article is intended for informational purposes only and does not constitute legal or medical advice. Readers should consult qualified legal counsel or regulatory professionals regarding specific compliance questions related to FDA compounding regulations.